Iranian Consensus Recommendations for Treatment of Myasthenia Gravis

Shahriar Nafissi ¹ * , Ali Asghar Okhovat ^1,2 , Farnaz Sinaei ¹, Behnaz Ansari ³, Hormoz Ayramloo ⁴, Keyvan Basiri ³, Reza Boostani ⁵, Bahram Haghi Ashtiani ⁶, Payam Sarraf ⁷, Farzad Fatehi ¹

Cited by CrossRef: 1

1- Jiang A, Hu Q, Wang Z, Wu F. Efficacy and Safety of Tacrolimus Therapy in Patients With Juvenile Myasthenia Gravis: A Single-Arm Meta-Analysis. Pediatric Neurology. 2025;166:32 [Crossref]

2- Chen J, Su C, Feng L, Wang H, Chen P, Cheng C, Huang X, Di L, Chen H, Ruan Z, Chang T, Zhou H, Da Y, Feng H. Effects of Thymectomy in Late‐Onset Myasthenia Gravis: A Multi‐Center Longitudinal Retrospective Study. Annals of Neurology. 2025; [Crossref]

3- Seok H. Steroid-induced spinal epidural lipomatosis in a patient with myasthenia gravis. Neurol Sci. 2022;43(7):4595 [Crossref]

4- Chen J, Su C, Feng H, Kaminski H. Can Non‐Thymomatous Late‐Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta‐Analysis. Euro J of Neurology. 2025;32(3) [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.